| Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer M Ligorio, S Sil, J Malagon-Lopez, LT Nieman, S Misale, M Di Pilato, ... Cell 178 (1), 160-175. e27, 2019 | 569 | 2019 |
| Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ... Cancer discovery 8 (6), 714-729, 2018 | 346 | 2018 |
| Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features R Buisson, A Langenbucher, D Bowen, EE Kwan, CH Benes, L Zou, ... Science 364 (6447), eaaw2872, 2019 | 303 | 2019 |
| MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer I Dagogo-Jack, S Yoda, JK Lennerz, A Langenbucher, JJ Lin, MM Rooney, ... Clinical Cancer Research 26 (11), 2535-2545, 2020 | 211 | 2020 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512-517, 2018 | 210 | 2018 |
| Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer JJ Lin, NJ Choudhury, S Yoda, VW Zhu, TW Johnson, R Sakhtemani, ... Clinical Cancer Research 27 (10), 2899-2909, 2021 | 144 | 2021 |
| Therapy-induced APOBEC3A drives evolution of persistent cancer cells H Isozaki, R Sakhtemani, A Abbasi, N Nikpour, M Stanzione, S Oh, ... Nature 620 (7973), 393-401, 2023 | 126 | 2023 |
| Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots P Jalili, D Bowen, A Langenbucher, S Park, K Aguirre, RB Corcoran, ... Nature Communications 11 (1), 2971, 2020 | 124 | 2020 |
| An extended APOBEC3A mutation signature in cancer A Langenbucher, D Bowen, R Sakhtemani, E Bournique, JF Wise, L Zou, ... Nature communications 12 (1), 1602, 2021 | 122 | 2021 |
| Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition JJ Lin, A Langenbucher, P Gupta, S Yoda, IJ Fetter, M Rooney, A Do, ... NPJ precision oncology 4 (1), 21, 2020 | 75 | 2020 |
| NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer H Guo, G Golczer, BS Wittner, A Langenbucher, M Zachariah, TD Dubash, ... Molecular cell 81 (19), 4041-4058. e15, 2021 | 73 | 2021 |
| Extracellular matrix proteins regulate NK cell function in peripheral tissues MD Bunting, M Vyas, M Requesens, A Langenbucher, EB Schiferle, ... Science advances 8 (11), eabk3327, 2022 | 52 | 2022 |
| Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018; 8: 714–29 S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ... ALKF1174L ALKF1174L ALKL1196Q ALKC1156Y ALKG1269A ALKR1264K ALKF1174L …, 0 | 50 | |
| Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers M Karaayvaz-Yildirim, RE Silberman, A Langenbucher, SV Saladi, ... Science Advances 6 (5), eaay2611, 2020 | 48 | 2020 |
| YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4 N Chen, G Golczer, S Ghose, B Lin, A Langenbucher, J Webb, H Bhanot, ... Cell reports 39 (11), 2022 | 38 | 2022 |
| APOBEC mutagenesis is concordant between tumor and viral genomes in HPV-positive head and neck squamous cell carcinoma DL Faden, KAL Kuhs, M Lin, A Langenbucher, M Pinheiro, M Yeager, ... Viruses 13 (8), 1666, 2021 | 35 | 2021 |
| A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells S Lee, D Micalizzi, SS Truesdell, SIA Bukhari, M Boukhali, ... Genome biology 21 (1), 33, 2020 | 30 | 2020 |
| RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer SB Koh, K Ross, SJ Isakoff, N Melkonjan, L He, KJ Matissek, A Schultz, ... Clinical Cancer Research 27 (17), 4883-4897, 2021 | 22 | 2021 |
| APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer H Isozaki, A Abbasi, N Nikpour, A Langenbucher, W Su, M Stanzione, ... BioRxiv, 2021.01. 20.426852, 2021 | 22 | 2021 |
| Antibody-peptide epitope conjugates for personalized cancer therapy S Zhang, C Yan, DG Millar, Q Yang, JM Heather, A Langenbucher, ... Cancer Research 82 (5), 773-784, 2022 | 17 | 2022 |
